Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 23:10:18.
doi: 10.21037/tgh-24-57. eCollection 2025.

KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer

David H Ilson  1
Affiliations
Editorial

KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer

David H Ilson. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: Neoadjuvant chemotherapy; gastric cancer; pathologic complete response; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-57/coif). The author has no conflicts of interest to declare.

Comment on

References

    1. Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024;25:212-24. 10.1016/S1470-2045(23)00541-7 - DOI - PubMed
    1. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:1571-80. 10.1001/jamaoncol.2020.3370 - DOI - PMC - PubMed
    1. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759-71. 10.1016/S0140-6736(21)01234-4 - DOI - PubMed
    1. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24:1181-95. 10.1016/S1470-2045(23)00515-6 - DOI - PubMed
    1. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40. 10.1016/S0140-6736(21)00797-2 - DOI - PMC - PubMed